Dr. Jinsong Liu is a professor with tenure in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center since 2009. He received his medical degree from Shanghai Medical University 1983 and completed his Ph.D. from Case Western Reserve University in 1991, and post-doctoral training at the University of Michigan in 1993, pathology residency and surgical pathology fellowship training at New York University in 1999. Dr. Liu is an internationally recognized for his expertise in diagnostic pathology and research achievements in ovarian cancer. Dr. Liu has co-authored 213 original publications and has been an editorial member of several reputable journals.
His research interest has focused on the mechanisms of epithelial tumorigenesis, inflammation, and cancer stem cells.
Thierry Virolle is a Research Director (permanent position) at Institut National de la Santé et de la Recherche Médicale (INSERM), Head of the Team Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity at the Institute of Biologie Valrose (iBV). He is Co-Founder of the French National Sud Cancer Stem Cell Network, SUNRiSE dedicated to the study of cancer stem cell.
Thierry Virolle is a Research Director (permanent position) at Institut National de la Santé et de la Recherche Médicale (INSERM), Head of the Team Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity
Dr. Xianming Mo is a professor of internal medicine and acts as Director of Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. He obtained his medicine degree from North Sichuan Medical College. Then he was trained in pathology and accept Master of Medicine in West China University of Medical Science. After obtaining a PhD degree in Peking Union Medical College, He moved to Humboldt-Universität zu Berlin and then to Medical College of Georgia as postdoctoral fellows. Then, he became junior faculty in Medical College of Georgia and senior scientist in Max Delbruck Center for Molecular Medicine. In 2006, he returned back to West China Hospital.
Xianming Mo is interested in understanding the biology of physiological and pathological tissue stem cells including hematopoietic stem cell, neural stem cell and epithelial stem cells. Now one of his works focuses on the biology of the cancer stem cells, the constitution of cancer tissues in human patients with carcinoma and the their therapeutic implications in cancer.
Dr Ilio Vitale received his Ph.D. in 2006 for the molecular characterization of mitotic catastrophe. During his 6-years post-doc in France he investigated the role of aneuploidy/tetraploidy in tumorigenesis uncovering surveillance mechanisms surveying cell ploidy (EMBOJ 2010, Science 2012). He is currently Group Leader and Adjunct Professor in Neuobiology at the University of Rome “Tor Vergata” working on the link between CSCs, chromosomal instability, and tumor immunity. His group recently identified a novel strategy for the depletion of CSCs based on CHK1 inhibition (Gut 2017, Mol Cell 2017). He is the Executive Editor of Molecular & Cellular Oncology, Subject Editor in the Reference Module in Life Sciences and served as Editor for several books. He received the Young Scientist Award from the European Environmental Mutagenesis Society (2013). He is author of >100 ISI papers (including Science, Nat Med, Nat Rev Mol Cell Biol., Nat Cell Biol). “h” index: 34.
role of genomic and chromosome instability in oncogenesis. In particular, we are investigating the molecular mechanisms for maintaining genomic stability in CSCs and also evaluating the immunogenic potential of CSCs, with the major aim of developing novel strategies for efficient tumor eradication.
Dr. Zhang graduated from Johns Hopkins University with PhD. He has worked at Harvard University Genome Center as Senior System Biologist for years before joining University of Hong Kong in 2013. Dr. Zhang lab has broad interest in genetic and epigenetic regulation in development and diseases. Currently, his lab is focusing on epigenetic regulation of tumorigenesis. His lab employs high through-put ‘omics’ assays and large scale computation to dissect the gene regulatory network and signaling pathways involved in oncogenesis.
Dr. Zhang lab has broad interest in genetic and epigenetic regulation in development and diseases. Currently, his lab is focusing on epigenetic regulation of tumorigenesis
Joo-Hyeon Lee was fascinated by stem cell research through Ph.D. studies under the supervision of Prof. Daesik Lim in KAIST, Korea. She then joined Prof. Carla Kim’s laboratory at Harvard Medical School where she became interested in the study of adult lung stem cells. She established her own research group at the Cambridge Stem Cell Institute in 2016 and focuses on understanding cellular behavior and regulatory networks of adult stem and niche cells. Joo-Hyeon is currently Faculty member at the Department of Physiology, Development, and Neuroscience, University of Cambridge and was recently awarded the Royal Society and Wellcome Trust Sir Henry Dale Fellowship and ERC starting grant.
Lee lab applies mouse genetics, ex vivo organoid co-cultures, live imaging, single-cell molecular analysis and mathematic modelling to define the identity and heterogeneity of diverse epithelial progenitor and mesenchymal populations, understand the key stem-mesenchymal interactions and the precise mechanisms that maintain tissue homeostasis and regeneration. Specifically, they are asking how the quiescent state is maintained and becomes activated, how cell fate is determined, and how niches develop and remodel in lung homeostasis, injury repair and early tumorigenesis.
Claire Acquaviva obtained her PhD at Montpellier University working on the proteolytic regulation of Fos transcription factors in Dr. Marc Piechaczyk’s laboratory at the Institute of Molecular Genetics of Montpellier (IGMM). She worked as a post-doc in Jonathon Pines’ laboratory at the Gurdon Institute in Cambridge (UK) on the regulation of the cell cycle by proteolysis. She returned to France in Marseille to work on the centrosome, primary cilia, cell cycle regulation and associated pathologies in Dr. Daniel Birnbaum’s laboratory at the CRCM.
Dr. Claire Acquaviva and Dr. Emilie Mamessier co-lead a group at the CRCM interested on Circulating Tumor Cells (CTCs) and their contribution to cancer metastases. Their main research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.
Emmanuelle Charafe-Jauffret is a doctor of medicine and a specialist in breast cancer, and is known for her expertise in cancer stem cells.
Emmanuelle Charafe-Jauffret, a doctor of medicine, is Professor of Hospitals and a specialist in breast cancer and is known for her expertise in cancer stem cells. She led a group on the characterization of cancer stem cells in the gland breast.
Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.
Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. Since 2002, Dr. Tang and his colleagues have been studying cancer stem cells and cancer cell heterogeneity with a focus on prostate cancer. His career goals are to identify novel therapeutics and therapeutic combinations for personalized cancer treatment.
Dr. Jingfang Ju is the Professor in the Department of Pathology at Stony Brook Medicine/Stony Brook University. Dr. Ju received his BS degree from the Northeastern University and Ph.D. in molecular biology and biochemistry at the University of Southern California. He completed his post-doctoral research fellowship at Yale Cancer Center, Yale University. Previously Dr. Ju has served as the Senior Scientist and Team Leader of high throughput genomics at a biopharmaceutical company, CuraGen Corporation in Connecticut.
Dr. Ju's major research interest is in the development of miRNA based therapeutics and biomarker in gastrointestinal cancer. The Ju laboratory studies the mechanisms of microRNAs in cancer stem cell resistance, epithelial to mesenchymal transition (EMT), autophagy, and apoptosis. His group made initial discovery of the regulatory relationship between p53 tumor suppressor and microRNA. Dr. Ju and his group discovered the superior stability of microRNA in archival formalin fixed paraffin embedded (FFPE) clinical specimens which serves as the foundation of microRNA based biomarker discovery.
A/Prof Yong Li obtained his PhD degree at University of New South Wales (UNSW) Sudney, Australia in 2000. He became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014; and an NHMRC Achievement Award (ranked No.1 in the industry fellow) in 2011. He was promoted to an Associate Professor in the Faculty of Medicine, UNSW since 2011, and a Principal Scientific Officer by the South Eastern Sydney Local Health District (SESLHD) since 2012. A/Prof Li has more than 100 career publications in cancer research area since 1999.
Associate Professor Li’s research is aimed at a): To investigate novel biomarkers from human body fluids and tissues, cancer cell lines and animal models for cancer diagnosis and monitoring cancer progression; b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance; c): To use targeted cancer therapy and combination therapy to control metastatic and therapeutic resistant cancers.
Dr Philippe Juin obtained his PhD degree in 1995 for his work on mitochondrial assembly. During his post-doc in the UK, he defined the mitochondrial apoptotic pathway as one major intrinsic tumor suppressor mechanism triggered by oncogene deregulation. As an Associate Researcher at INSERM, he led increasingly ambitious investigations of the regulation of the mitochondrial apoptotic pathway by Bcl-2 family members in human cancer cells and he created in 2012 an INSERM team that specifically focusses on the role of this pathway in stress adaptation and tumor escape. This team gained international recognition for its fundamental and translational research on the regulation of therapeutic response and tumor progression by BCL-2 family members (Nature Rev. Cancer 2013, Cell Rep. 2016, EMBO Rep. 2018 in press). This team contributed to establish that changes in mitochondrial apoptotic priming are at the core of breast cancer cells response to cytotoxic stress and treatments, being influenced by oncogene signaling, tumor suppressor pathways, therapy and tumor context. This team recently established a new function of BCL-2 members, that contributes contributing to the self renewal of breast cancer initiating cells, and defined the molecular events involved (Nature Comm., 2017).
Dr Philippe Juin and his team specifically focusses on the role of this pathway in stress adaptation and tumor escape